CASE REPORT

Fatal pulmonary *Mycobacterium xenopi* in a patient with rheumatoid arthritis receiving etanercept

Nimrod Maimon, James Brunton, Adrienne K Chan, Theodore K Marras

Thorax 2007;62:739–740. doi: 10.1136/thx.2005.056952

Mycobacterium xenopi is a water-related mycobacterium with low pathogenicity in humans. Little is known about the association between anti-tumour necrosis factor (TNF) α and non-tuberculous mycobacterial infections. The case history is presented of fatal *M xenopi* infection in a patient receiving anti-TNF α treatment.

Mycobacterium *xenopi* is a water-related mycobacterium with low pathogenicity in humans. Although the association between anti-tumour necrosis factor (TNF) α treatment and *Mycobacterium tuberculosis* is well known,^{1,2} relatively little is known about the association with non-tuberculous mycobacterial infections. We present the first case of fatal *M xenopi* infection in a patient receiving anti-TNF α treatment.

CASE REPORT

A 71-year-old Caucasian man was admitted to our institution in 2005 with progressive dyspnoea and weight loss over the preceding 12 months. He had moderate to severe emphysema and severe rheumatoid arthritis, previously well controlled with methotrexate and prednisone. In 2002 he experienced an acute exacerbation of the rheumatoid arthritis and the TNF α receptor antagonist etanercept was started. He had a complete response to the new medication and no side effects were noted. However, less than 12 months later he was admitted to another hospital with increasing dyspnoea, productive cough and weight loss. A chest radiograph revealed a new left upper lobe consolidation and macrolide treatment was initiated. After 2 weeks with an incomplete response he underwent bronchoscopy which yielded negative bacteriological assessment, negative acid-fast

stain and mycobacterial cultures. However, sputum collected before starting treatment grew *M xenopi*. He improved after a few weeks of macrolide monotherapy and about 18 months later, after 12 months of progressive dyspnoea and weight loss, he was referred to our centre for further assessment. A CT scan (fig 1) revealed extensive emphysema in the right lung and near complete destruction of the left lung with air-liquid levels.

Bronchoscopic examination was positive for *M xenopi* only. Treatment with rifampicin, ethambutol and clarithromycin was initiated and immunosuppressive medications for rheumatoid arthritis (including etanercept) were discontinued. Unfortunately the patient was unable to tolerate the initial antimycobacterial drug regimen and also refused parenteral aminoglycoside therapy. Over the subsequent 9 months he tolerated only intermittent single agent therapy and continued to deteriorate. He was admitted to his regional hospital for palliative inpatient care and died from respiratory failure and wasting illness.

DISCUSSION

Etanercept is a genetically engineered dimer of the soluble TNF α receptor II in which the extracellular domain of the p75 receptor has been fused to the Fc portion of IgG₁. This agent has been used effectively in a variety of rheumatological diseases.³ Treatment with etanercept in short-term clinical trials has been reported to be well tolerated, but post-marketing surveillance has identified serious infectious side effects. TNF α has been shown to play a central role in the formation and maintenance of granulomas that contain and kill mycobacteria. It also appears to reduce tissue damage caused by the inflammatory response.⁴ Cases of reactivation of tuberculosis associated with the use of TNF α antagonists have led to a requirement for patients to be screened for active and latent tuberculosis before anti-TNF α treatment is given.

Mycobacterium xenopi is a water-related mycobacterium with low pathogenicity. Because of increased frequency of isolation of this organism and the relative infrequency of advanced infection, caution is advised in interpreting the clinical significance of *M xenopi* isolation.⁵ In our case, the diagnosis was established by repeated isolation of *M xenopi* in the setting of severe progressive systemic and pulmonary disease and in the absence of other pathogens. In view of our patient's unsuccessful clinical course, it is suggested that a thorough pulmonary assessment should be performed before introducing etanercept or other anti-TNF α medication. In the presence of underlying lung disease such as emphysema, bronchiectasis or fibrosis, or in the presence of radiographic signs of current or prior pulmonary infection, assessment should include respiratory cultures for mycobacteria and fungi. Positive cultures for non-tuberculous mycobacteria mandate either pre-emptive treatment or close monitoring for progression if TNF α inhibition is initiated. A decision as to whether a patient with

Figure 1 CT scan showing extensive emphysema in the right lung and near complete destruction of the left lung with air-liquid levels.

Abbreviation: TNF α , tumour necrosis factor α

pulmonary non-tuberculous mycobacteria requires antimycobacterial treatment before receiving a TNF α inhibitor may be difficult and should involve clinicians with expertise in mycobacterial infection.

Authors' affiliations

N Maimon, Division of Respiriology, University Health Network and Mount Sinai Hospital, Department of Medicine, University of Toronto, Toronto, Canada

J Brunton, A K Chan, Division of Infectious Diseases, University Health Network and Mount Sinai Hospital, Department of Medicine, University of Toronto, Toronto, Canada

T K Marras, Department of Respiratory Medicine, University Health Network and Mount Sinai Hospital, Department of Medicine, University of Toronto, Toronto, Canada

NM is supported by the Princess Margaret Hospital Foundation, Toronto, Canada and SACTA-RASHI Foundation, Israel.

Competing interests: None.

Correspondence to: Dr Theodore K Marras, Toronto Western Hospital, 7 East, Room 452, 399 Bathurst Street, Toronto, Ontario, Canada M5T 2S8; ted.marras@utoronto.ca

Received 5 December 2005

Accepted 27 February 2006

REFERENCES

- 1 **Keane J**, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor- α neutralizing agent. *N Engl J Med* 2001;**345**:1098–104.
- 2 **Keane J**, Gershon SK, Braun MM. Tuberculosis and treatment with infliximab. *N Engl J Med* 2002;**346**:625–6.
- 3 **Criscione L**, St Clair EW. Tumor necrosis factor- α antagonists for the treatment of rheumatic diseases. *Curr Opin Rheumatol* 2002;**14**:204–11.
- 4 **Gardam M**, Keystone E, Menzies R, et al. *Lancet Infect Dis* 2003;**3**:148–55.
- 5 **Jiva TM**, Jacoby HM, Weymouth LA, et al. *Mycobacterium xenopi*: innocent bystander or emerging pathogen? *Clin Infect Dis* 1997;**24**:226–32.

LUNG ALERT

Suggested person-to-person transmission of *Mycobacterium bovis*

▲ Evans JT, Smith EG, Banerjee A, et al. Cluster of human tuberculosis caused by *Mycobacterium bovis*: evidence for person-to-person transmission in the UK. *Lancet* 2007;**369**:1270–6.

M*ycobacterium bovis* is felt to be primarily a zoonotic disease occasionally transmitted to humans who are immunocompromised and either have contact with cattle or consume unpasteurised dairy products. An epidemiological investigation using DNA fingerprinting and surveillance data from the UK Mycobacterial Surveillance Network and the Veterinary Laboratories Agency identified a cluster of six people infected with *M bovis* in the West Midlands between 2004 and 2006. Five of the subjects' disease manifested as pulmonary disease and one died of *M bovis* meningitis. The demographics of the infected cluster were unusual for *M bovis* infection because 1) all subjects were young and UK born; 2) only one of the six had consumed unpasteurised dairy products; 3) two of the six subjects were immunocompetent; and 4) the subjects were linked by social networks in a local bar and a city centre nightclub. All isolates were pyrazinamide resistant, which is typical of *M bovis*.

This study describes a cluster of cases of *M bovis* in a setting more commonly associated with *M tuberculosis*, suggesting human-to-human transmission.

Asha Garg

MD, MPH, Charlotte, North Carolina, USA; ashagargstern@yahoo.com